Updates to Reflect 'recommended International Non-proprietary Names'

The Prescription Pricing Authority (PPA) will be making changes to the names of certain medicinal products as advised by the Medical and Healthcare products Regulatory Agency (MHRA).

The proposed changes will reflect the 'recommended International Non-proprietary Names' (rINN) for virtually all medicinal substances where the British Approved Names (BANs) naming convention is currently used (with the exception of adrenaline and noradrenaline).

The decision to move from the BAN naming convention to the rINN was taken after consultation between the MHRA, Department of Health (DH), the Devolved Administrations and endorsed by independent advice from the Medicines Commission.

Implementation Date

PPA systems, reports, and Primary Care Drug Dictionary will reflect these changes from 1 December 2003.

Any queries regarding this matter should be directed to the PPA's Pharmaceutical Advisory Helpdesk by telephoning **0191 203 5274** or **0191 203 5275**.

.